Study to Evaluate Resistance Mechanisms and Real-world Pharmacoeconomics of Crizotinib in NSCLC Patients

UnknownOBSERVATIONAL
Enrollment

29

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

March 31, 2018

Study Completion Date

June 30, 2018

Conditions
Non-small Cell Lung Cancer Metastatic
Trial Locations (8)

K1H 8L6

Ottawa Hospital, Ottawa

M5G 2M9

Princess Margaret Hospital, Toronto

H3T 1E2

McGill University Health Center (JGH, St-Mary's, MGH, RVH), Montreal

H4J 1C5

Hôpital du Sacré-Coeur de Montréal, Montreal

Unknown

Centre hospitalier de l'Université de Montréal, Montreal

G5L 5T1

CSSS Rimouski, Rimouski

J1H 5N4

Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke

G1V 4G5

Institut Universitaire de cardiologie et de pneumonologie, Québec

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

collaborator

Quebec Clinical Research Organization in Cancer

OTHER

collaborator

PeriPharm

OTHER

collaborator

Personalized Medicine Partnership for Cancer

OTHER

lead

Jewish General Hospital

OTHER